Regeneron Pharmaceuticals (REGN) EBT (2009 - 2026)

Regeneron Pharmaceuticals has reported EBT for 18 years, with the latest figure at $831.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 8.15% year-over-year to $831.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 billion (up 3.46% YoY), and the FY2025 full-year result was $5.2 billion, up 9.43% from the prior year.
• EBT for Q1 2026 stood at $831.2 million, down from $1.0 billion in the prior quarter.
• The five-year high for EBT was $1.8 billion in Q3 2025, with the low at $700.7 million in Q1 2024.
• Average EBT over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2023.
• Year-over-year, EBT slumped 74.33% in 2022 and jumped 50.35% in 2024.
• Tracing REGN's EBT over 5 years: stood at $1.3 billion in 2022, then retreated by 13.37% to $1.1 billion in 2023, then retreated by 16.51% to $958.1 million in 2024, then advanced by 8.93% to $1.0 billion in 2025, then declined by 20.36% to $831.2 million in 2026.
• The last three EBT figures came in at $831.2 million (Q1 2026), $1.0 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.

Peer Comparison